News

BVBiomedical Ltd is pleased to announce that it has been selected by Business Magazine as one of the top 100 life science companies in 2024.

BVBiomedical Ltd was awarded a grant from the SIGHT programme for corporate development (https://www.sightprogramme.co.uk/).

BVBiomedical Ltd were invited to present to the executive board of UK TBI-Reporter on the use of relaxin in the treatment of concussion and TBI.

BVBiomedical Ltd was invited to the Department of Health and Social Care to attend a round table discussion on the prevention and treatment of concussion in sport.

BVBiomedical Ltd entered into a collaboration with Innovate UK Business Growth, The national innovation & growth service for ambitious businesses (https://iuk.ktn-uk.org/business-growth/).

Australian Patent No. 2016320544 in the name of BVBiomedical Limited For a Novel Therapy was granted.

United States Patent No. 11344607 in the name of BVBiomedical Limited For a Novel Therapy was granted.

BVBiomedical Ltd entered into a collaboration with Cognition Health, London to develop a clinical trial protocol for the use of relaxin to treat CTE in retired rugby players.